

3. Larijani GE, Goldberg ME, Azad SS, Marr AT, Lessin JB, Hood LE, Ascher J, Rudd GD, Seltzer JL: The efficacy of doxacurium chloride for endotracheal intubation and provision of neuromuscular blockade in patients anesthetized with enflurane. *Anesth Analg* 67:S128, 1988
4. Katz RL: Modification of the action of pancuronium by succinylcholine and halothane. *ANESTHESIOLOGY* 35:602-606, 1971
5. Walts LF, Rusin WD: The influence of succinylcholine on the duration of pancuronium neuromuscular blockade. *Anesth Analg* 56:22-25, 1977
6. D'Hollander AA, Agoston S, DeVille A, Cuvelier F: Clinical and pharmacological actions of a bolus injection of suxamethonium: Two phenomena of distinct duration. *Br J Anaesth* 55:131-134, 1983
7. Krieg N, Hendrickx HL, Crul JF: Influence of suxamethonium on the potency of ORG NC 45 in anaesthetized patients. *Br J Anaesth* 53:259-261, 1981
8. Stirt JA, Murray AL, Katz RL, Schehl DC, Lee C: Atracurium during halothane anesthesia in humans. *Anesth Analg* 62:207-210, 1983
9. Walts LF, Dillon JB: Clinical studies of the interaction between d-tubocurarine and succinylcholine. *ANESTHESIOLOGY* 31:39-44, 1969
10. Walts LF, Dillon JB: Clinical studies on succinylcholine chloride. *ANESTHESIOLOGY* 28:372-376, 1967
11. Stirt JA, Katz RL, Murray AL, Schehl DL, Lee C: Modification of atracurium blockade by halothane and by suxamethonium. *Br J Anaesth* 55:71-75S, 1983
12. Waud DR: The nature of depolarization block. *ANESTHESIOLOGY* 29:1014-1024, 1968

Anesthesiology
69:607-608, 1988

Cimetidine and Succinylcholine: Potential Interaction and Effect on Neuromuscular Blockade in Man

JOSEPH A. STIRT, M.D.,* RICHARD J. SPERRY, M.D.,† COSMO A. DIFAZIO, M.D., PH.D.‡

Cimetidine, a histamine H₂ receptor antagonist, is often used as a premedication to increase gastric fluid pH. Cimetidine decreases liver blood flow¹ and inhibits microsomal drug metabolism.² In addition, *in vitro* inhibition of pseudocholinesterase activity by cimetidine has been demonstrated.³ Since succinylcholine is metabolized by pseudocholinesterase formed in the liver, a potential exists for interaction between cimetidine and succinylcholine. Indeed, one recent study has demonstrated a markedly prolonged time to recovery of neuromuscular function after succinylcholine in patients receiving cimetidine *versus* controls during halothane anesthesia.⁴ This prospective study was designed to determine the effect of cimetidine premedication on the onset and duration of succinylcholine-induced neuromuscular blockade in patients anesthetized with nitrous oxide and fentanyl.

METHODS AND MATERIALS

This study was approved by the institution's Human Investigation Committee, and written informed consent was obtained from each patient. The subjects were 20 adult patients, ASA physical status 1 or 2, scheduled for elective surgery. The patients were randomly allocated into two groups of 10 each. Group 1 patients received cimetidine 400 mg p.o. at bedtime and 400 mg p.o. 90 min prior to induction of anesthesia. Group 2 patients acted as controls and did not receive cimetidine. No other premedication was given.

After placement of an arterial blood pressure cuff and EKG electrodes, anesthesia was induced with thiopental 4-6 mg/kg iv and maintained with fentanyl 3-5 µg/kg iv and N₂O, 67% in O₂. Succinylcholine 1 mg/kg iv was administered 3 min after thiopental.

Neuromuscular blockade was monitored with a force transducer (Grass FT-10) which measured adductor pollicis twitch tension in response to supramaximal ulnar nerve stimulation at 0.15 Hz, delivered for a duration of 0.15 ms via 25-gauge needles placed subcutaneously. A strip chart continuously recorded the force transducer measurements from 2 min before to 50 min after succinylcholine administration.

Times to initial twitch depression and to maximal neuromuscular blockade and the magnitude of neuromuscular block were measured, as were times to 10, 25, 50, 75, and 90% recovery of initial twitch tension. Student's *t* test was used to test statistical significance between groups, with *P* < 0.05 considered significant.

* Associate Professor of Anesthesiology, University of Virginia Medical Center.

† Assistant Professor of Anesthesiology, University of Utah Health Science Center.

‡ Professor of Anesthesiology, University of Virginia Medical Center.

Received from the Department of Anesthesiology, University of Virginia Medical Center, Charlottesville, Virginia; and the Department of Anesthesiology, University of Utah Health Science Center, Salt Lake City, Utah. Accepted for publication May 10, 1988.

Address reprint requests to Dr. Stirt: Department of Anesthesiology, Box 238, University of Virginia Medical Center, Charlottesville, Virginia 22908.

Key words: Antagonists: cimetidine. Interactions (drug). Neuromuscular relaxants: succinylcholine.

TABLE 1. Characteristics of Succinylcholine-induced Neuromuscular Block and Recovery With and Without Cimetidine Premedication

	Maximal Block (%)	Time to Initial Twitch Height Depression (min)	Time to Maximal Block (min)	Time to Recovery (min)				
				10%	25%	50%	75%	90%
Cimetidine	98.0 ± 6.3	0.7 ± 0.3	1.4 ± 0.7	7 ± 2	8 ± 2	9 ± 3	10 ± 3	10 ± 3
Control	98.8 ± 3.8	0.7 ± 0.2	1.6 ± 0.4	7 ± 2	8 ± 2	9 ± 3	10 ± 3	11 ± 3

All values are mean ± SD.

RESULTS

Maximal neuromuscular block (twitch tension depression) and times to initial and maximal twitch depression for the two groups are shown in table 1. The administration of cimetidine had no effect on the neuromuscular blockade produced by succinylcholine. Times to various % recovery (10, 25, 50, 75, and 90%), a measure of duration of neuromuscular blockade, are also shown in table 1. There was no significant difference at any % recovery of initial twitch height from succinylcholine between patients given cimetidine and controls.

DISCUSSION

Cimetidine alters the effects of many drugs commonly used during anesthesia, including opioids,⁵ benzodiazepines,⁶ and beta adrenergic blockers.¹ Proposed mechanisms for cimetidine-induced changes are a reduction in liver blood flow¹ and inhibition of liver microsomal enzyme systems.²

After iv injection of a dose of succinylcholine, the drug is distributed throughout the extracellular space and to the neuromuscular junction. The plasma levels and the clinical effects of succinylcholine dissipate because of its breakdown in plasma. Pseudocholinesterase levels must be markedly reduced before any prolongation of succinylcholine-induced neuromuscular block occurs, and cimetidine should not have any effect on pseudocholinesterase produced before its administration. Thus, a prolonged effect of succinylcholine after cimetidine would not be expected unless cimetidine levels proved to be high enough to cause major reductions in pseudocholinesterase levels.

In a recent laboratory study,³ it was found that cimetidine significantly inhibits pseudocholinesterase, the minimum cimetidine concentration producing a significant inhibition (50%) of pseudocholinesterase activity being 2.1×10^{-3} M. However, during chronic cimetidine treatment in man, serum drug levels are 0.5×10^{-5} to 2.0×10^{-5} M.³ Based on *in vitro* analysis of pseudocholinesterase inhibition by cimetidine, one would predict less than 1% inhibition of pseudocholinesterase activity *in vivo* at these serum cimetidine concentrations.³

The predictions based on *in vitro* analysis, as noted above, are consistent with the findings of our study. In contrast to a previous study,⁴ we found no differences in the duration of succinylcholine-induced neuromuscular blockade between cimetidine-treated and control groups. The reason for the discrepancy between our results and those reported previously⁴ is unclear.

We used a force transduction method to monitor neuromuscular blockade; in contrast, the earlier study⁴ employed the evoked EMG. Nevertheless, it is difficult to impute this difference in monitoring methodology as the reason why the previous study demonstrated a 150% increase in the duration of action of succinylcholine in patients given prior cimetidine, whereas ours showed no difference.

The earlier study⁴ employed halothane/N₂O anesthesia while we used fentanyl/N₂O. Whether this is enough to explain the qualitative difference in results remains problematic. If it is sufficient, then one would have to infer either a cimetidine-halothane-succinylcholine interaction, or inhibition by fentanyl of a cimetidine-succinylcholine interaction, neither of which has been reported. We view neither of these as likely, and therefore suggest that cimetidine and succinylcholine do not interact to produce clinically relevant prolongation of succinylcholine-induced neuromuscular blockade.

REFERENCES

1. Freely J, Wilkinson GR, Wood AJJ: Reduction of liver blood flow and propranolol metabolism by cimetidine. *N Engl J Med* 304: 692-695, 1981
2. Purunen J, Sotaniemi E, Pelkonen D: Effect of cimetidine on microsomal drug metabolism in man. *Eur J Clin Pharmacol* 18: 185-187, 1980
3. Hansen WE, Bertl S: The inhibition of acetylcholinesterase and pseudocholinesterase by cimetidine. *Arzneimittelforschung* 33: 161-163, 1983
4. Kambam JR, Dymond R, Krestow M: Effect of cimetidine on duration of action of succinylcholine. *Anesth Analg* 66:191-192, 1987
5. Sorkin EM, Ogawa GS: Cimetidine potentiation of narcotic action. *Drug Intell Clin Pharm* 17:60-61, 1981
6. Greenblatt DJ, Abernathy DR, Morse DS, Harmatz JS, Shader RI: Clinical importance of the interaction of diazepam and cimetidine. *N Engl J Med* 310:1639-1643, 1984